The GRACE study was specifically designed to compare the efficacy, incidence of adverse events, and tolerability over 48 weeks of darunavir/ritonavir (DRV/r) 600 mg/100mg twice daily combined with an investigator-selected optimized background regimen in ARV-experienced women and men.